Story

Grand Pharma's Cancer Diagnostic GPN01530-2 Receives FDA Fast Track Designation

ENTHMSVIIDZHZH-TWJAKOHI
Aug 9, 20262 min read
Grand Pharma's Cancer Diagnostic GPN01530-2 Receives FDA Fast Track Designation
Text size
Background

Grand Pharmaceutical (00512.HK) announced its internally developed, innovative radiopharmaceutical drug conjugate (RDC), GPN01530-2, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designation is for the drug's use in diagnosing solid tumors.

Designation to Expedite Development

The FDA's Fast Track program is designed to facilitate the development and hasten the review of drugs intended to treat serious conditions and fill an unmet medical need. According to the company's announcement, this designation allows for more frequent communication with the FDA and eligibility for Accelerated Approval and Priority Review, if relevant criteria are met.

The status also permits a rolling review of the New Drug Application (NDA), enabling the company to submit completed sections for review rather than waiting for the entire application to be finished. GPN01530-2 had previously received FDA clearance to proceed with Phase I/II clinical trials in the United States.

A Novel Imaging Agent

GPN01530-2 is a small-molecule RDC that targets Fibroblast Activation Protein (FAP), a protein highly expressed in over 90% of epithelial tumors but found at low levels in healthy tissue, making it a promising target for cancer diagnosis and therapy. The drug is positioned as a potential improvement over the current standard PET/CT imaging agent, 18F-FDG, which the company notes has relatively low sensitivity.

Sample IUX Markets – In-articleAd

Grand Pharma stated that preclinical and early human investigator-initiated studies showed GPN01530-2 has a good safety profile, rapid tumor targeting, and superior pharmacokinetic properties. The company reported that the agent demonstrated better clinical image contrast and more accurate detection of positive lesions compared to 18F-FDG.

Market Context and Strategy

This regulatory milestone supports Grand Pharma's global expansion in the nuclear medicine and anti-tumor sector, which utilizes a "US-China dual filing" international registration strategy. The global market for radiopharmaceuticals is projected to grow from $9.7 billion in 2024 to $57.3 billion by 2035, according to market data cited by the company, driven by technological advances and an aging population.

The company has established a significant presence in the field, with a pipeline of 16 innovative RDC and interventional oncology products. It recently completed a new radiopharmaceutical R&D and production base in Chengdu, China, which it describes as a platform covering the entire industry chain from isotope preparation to commercialization.

Read next

More on Stocks
Back to latest news

LATEST